Out-Licensing

SHI Link currently has the following technologies available for partnering:

A marketed hormone replacement therapy for regions outside of the US and Europe
Locus Pharmaceuticals' novel pre-clinical and clinical stage anti-mitotic, anti-angiogenic and anti-inflammatory compounds to be licensed for medical device applications
Monoclonal antibodies targeting clusterin
Intranasal Therapeutics' Phase III intranasal hydromorphone for acute trauma pain is available for all regions worldwide
Intranasal Therapeutics' nasally administered benzodiazepine in Phase I development is available for all regions outside of the US

SHI Link is also assisting Allon Therapeutics in its business development efforts.

In-Licensing

SHI Link currently is engaged to find: